# Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

> **NCT04869800** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 32 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** CKD-398
- **DRUG:** CKD-501, D745

## Key facts

- **NCT ID:** NCT04869800
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-27
- **Primary completion:** 2021-06-07
- **Final completion:** 2021-06-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04869800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04869800, "Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04869800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*